2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
6
Triple Negative Breast Neoplasms
4
Lung Neoplasms
4
Endometrial Neoplasms
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Breast Neoplasms
3
Small Cell Lung Carcinoma
2
Melanoma
2
Carcinosarcoma
2
Bile Duct Neoplasms
2
Advanced Solid Tumours
2
Uterine Cervical Neoplasms
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumour Refractory to Conventional Treatment
1
Salivary Gland Neoplasms
1
SCLC
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Non Small Cell Lung Cancer NSCLC
1
Neoplasms by Site
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Interventions
Rituximab
416
Cyclophosphamide
348
Vincristine
173
Prednisone
172
Doxorubicin
168
Etoposide
160
Peripheral Blood Stem Cell Transplantation
114
Filgrastim
108
Lenalidomide
97
fludarabine phosphate
96
Radiotherapy
80
Cytarabine
80
Gemcitabine
73
Melphalan
66
Mycophenolic Acid
64
Cyclosporine
60
Methotrexate
59
Busulfan
57
Ifosfamide
55
Carmustine
55
fludarabine
50
Tacrolimus
50
Whole-Body Irradiation
49
Carboplatin
49
polatuzumab vedotin
44
Oxaliplatin
44
Dexamethasone
44
Antilymphocyte Serum
42
ibrutinib
40
Bendamustine Hydrochloride
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Large B-Cell, Diffuse
×
ceralasertib
×
Clear all
NCT03527147
2022-08-15
PRISM
Acerta Pharma BV
Phase 1
Completed
30 enrolled